Tempus Expands Collaboration with Gilead to Enhance Oncology Pipeline

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 1 hour ago

0mins

GILD+1.97%

TEM+1.46%

Should l Buy GILD?

Source: Newsfilter

Collaboration Expansion: Tempus AI has announced a multi-year expanded collaboration with Gilead Sciences aimed at advancing Gilead's oncology research and development through Tempus' multimodal data repository, enhancing the effectiveness of clinical decision-making.
Data-Driven Innovation: Gilead will gain enterprise-wide access to Tempus' AI-driven Lens platform, enabling the use of broader datasets for trial design and biomarker strategies, thereby accelerating the new drug development process.
Patient-Centric Goals: Patrick Loerch, SVP of Clinical Data Science at Gilead, stated that this partnership reflects a shared commitment to improving cancer care quality by combining scientific expertise with real-world data insights.
Technology Empowerment: Tempus CEO Ryan Fukushima emphasized that by providing multimodal data, Gilead's team will be better equipped to leverage AI insights, increasing the probability of successfully developing life-altering medicines and driving significant breakthroughs in oncology.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on GILD

Wall Street analysts forecast GILD stock price to fall

19 Analyst Rating

16 Buy

3 Hold

0 Sell

Strong Buy

Current: 141.540

Low

105.00

Averages

137.88

High

154.00

Current: 141.540

Low

105.00

Averages

137.88

High

154.00

Truist

Gregory Renza

Buy

maintain

$152 -> $155

2026-04-08

New

Reason

Truist

Gregory Renza

Price Target

$152 -> $155

AI Analysis

2026-04-08

New

maintain

Buy

Reason

Truist analyst Gregory Renza raised the firm's price target on Gilead to $155 from $152 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm is looking for its management commentary on Yeztugo launch strategy and payer access dynamics in U.S./EU markets and any anito-cel launch preparation updates ahead of the December 23, 2026 PDUFA, Truist added.

RBC Capital

Sector Perform

maintain

$118 -> $123

2026-04-07

New

Reason

RBC Capital

Price Target

$118 -> $123

2026-04-07

New

maintain

Sector Perform

Reason

RBC Capital raised the firm's price target on Gilead to $123 from $118 and keeps a Sector Perform rating on the shares as part of the firm's broader research note previewing Q1 results in Biotech. Seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in Q1 by weather impact, particularly for launching and in-clinic products, but the robust return of M&A, coupled with clarity on limited tariff/Most Favored Nation drug pricing impacts, could help offset both this and broader macro volatility while keeping sector perceptions favorable, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GILD

Unlock Now

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Gilead Sciences Stock Falls 1.2% Following Announcement of Up to $5 Billion Acquisition of Germany's Tubulis

2 days agomoomoo

Stock Performance: Gilead Sciences shares have decreased by 1.2% following a significant acquisition.
Acquisition Details: The company has agreed to buy German biotech firm, which is valued at up to $5 billion.

Gilead Acquires German Biotech Tubulis in Deal Worth Up to $5 Billion

2 days agoBarron's

Acquisition Announcement: Gilead Sciences has announced its agreement to acquire German biotech company Tubulis GmbH.
Financial Details: The cash deal is valued at up to $5 billion, aimed at enhancing Gilead's cancer drug pipeline.